Afeyan warns U.S. science backlash could slow biotech innovation
TL;DR Summary
Investor Noubar Afeyan warns in his annual letter that a domestic backlash against science and policy cuts could slow biomedical advances, threaten life expectancy, and widen the gap with China, a message delivered at the JPMorgan Healthcare Conference.
Topics:business#biotech-policy#flagship-pioneering#jpmorgan-healthcare-conference#noubar-afeyan#science#science-backlash
- Investor behind Moderna says U.S. policy is ‘taking a sledgehammer to our miracle machine’ statnews.com
- ‘An undoing of the scientific method’: Flagship CEO warns of government threats to US biotech industry Fierce Biotech
- Moderna chair warns of ‘dystopia’ amid US science pullback Yahoo
- Flagship CEO Calls Out Attacks on Science, Warns of China Dominance BioSpace
- Pharmalittle: We're reading about a 'sledgehammer' to innovation, longevity medicine, and more statnews.com
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
91%
425 → 38 words
Want the full story? Read the original article
Read on statnews.com